Mifepristone: clinical application in general gynecology

Morales AJ, A J Morales, Arlene J. Morales, L M Kettel, Kettel LM, L. Michael Kettel, Murphy AA, Ana A. Murphy, A A Murphy
Clinical Obstetrics and Gynecology · 1996 · vol. 39(2) , pp. 451–460 · doi:10.1097/00003081-199606000-00018 · PMID:8734009 · W2079946594
Review OA: closed CC0
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-28 ⓘ

Mifepristone (RU-486) suppresses ovulation, causes endometrial changes, and shows efficacy in treating endometriosis, uterine fibroids, and potentially PMS, ectopic pregnancy, and anovulatory bleeding, though optimal dosage requires further study.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

RU-486, the first clinically available antiprogestin, has numerous gynecologic applications beyond first-trimester pregnancy termination. Long-term administration of 2 mg/day of RU-486 suppresses ovulation while maintaining serum estrogen levels and ovarian follicular activity. In the endometrium, long-term RU-486 administration results in significant endometrial dysynchrony and stromal compaction. RU-486 has been demonstrated to relieve pain in women with symptomatic endometriosis and decrease the size of uterine leiomyomata by about 50%. There are preliminary findings indicating that RU-486 is effective in the treatment of premenstrual syndrome, ectopic pregnancy, and anovulatory uterine bleeding. In need of further investigation is the RU-486 dosage that can treat pathophysiologic states while minimizing the endometrial effects.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Endometrium Genital Diseases, Female Hormone Antagonists Menstrual Cycle Mifepristone Endometriosis Endometriosis Endometriosis Endometrium Endometrium Female Female Genital Diseases, Female Genital Diseases, Female Hormone Antagonists Hormone Antagonists Humans Humans Leiomyoma Leiomyoma

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (36)

Source provenance

europepmc
last seen: 2026-10-04T09:26:46.659050+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-08T21:59:49.088203+00:00
unpaywall
last seen: 2026-10-10T06:25:47.132674+00:00
License: CC0 · commercial use OK